Infections Caused by Fusarium Species

REFERENCES

• Torres HA, Kontoyiannis DP. Hyalohyphomycosis (other than Aspergillosis and Penicilliosis). In: Dismukes WE, Pappas PG and Sobel JD, eds. Oxford Textbook of Clinical Mycology. 1st ed. New York, NY: Oxford University Press. 2003: 252–270.
   Google Scholar
• Boutati El, Anaissie EJ. Fusarium, a significant emerg-ing pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for man-agement. Blood 1997; 90 (3): 999–1008.
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoi-etic stem cell transplant recipients. Clin Infect Dis 2002; 34 (7): 909–917.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Groll AH. Emerging fungal pathogens: evolv-ing challenges to immunocompromised patients for the twen-ty-first century. Transpl Infect Dis 1999; 1 (4): 247–261.
   PubMedGoogle Scholar
• Girmenia C, Pagano L, Corvatta L, Mele L, del Favero A, Martino P. The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme. Br J Haematol 2000; 111 (1): 272–276.
   PubMed Web of Science ®Google Scholar
• Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003; 37 (2): 221–229.
   PubMed Web of Science ®Google Scholar
• Martino P, Gastaldi R, Raccah R, Girmenia C. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect 1994; 28 Suppl 1: 7–15.
   PubMedGoogle Scholar
• Raad I, Tarrand J, Hanna H, et al. Epidemiology, mole-cular mycology, and environmental sources of Fusarium infec-tion in patients with cancer. Infect Control Hosp Epidemiol 2002; 23 (9): 532–537.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Boktour M, Mays S, Duvic M, Kontoyiannis D, Hachem R, et al. Skin lesions associated with Fusarium infection. J Am Acad Dermatol 2002; 47 (5): 659–666.
   PubMed Web of Science ®Google Scholar
• Rabodonirina M, Piens MA, Monier MF, Gueho E, Fiere D, Mojon M. Fusarium infections in immunocompro-mised patients: case reports and literature review. Eur J Clin Microbiol Infect Dis 1994; 13 (2): 152–161.
   PubMed Web of Science ®Google Scholar
• Letscher-Bru V, Campos F, Waller J, Randriamahazaka R, Candolfi E, Herbrecht R. Successful outcome of treatment of a disseminated infection due to Fusarium dimerum in a leukemia patient. J Clin Microbiol 2002; 40 (3): 1100–1102.
   PubMed Web of Science ®Google Scholar
• Mayayo E, Pujol I, Guarro J. Experimental pathogenici-ty of four opportunist Fusarium species in a murine model. J Med Microbiol 1999; 48 (4): 363–366.
   PubMed Web of Science ®Google Scholar
• Richardson SE, Bannatyne RM, Summerbell RC, Milliken J, Gold R, Weitzman SS. Disseminated fusarial infec-tion in the immunocompromised host. Rev Infect Dis 1988; 10 (6): 1171–1181.
   PubMedGoogle Scholar
• Merz WG, Karp JE, Hoagland M, Jett-Goheen M, Junkins JM, Hood AF. Diagnosis and successful treatment of fusariosis in the compromised host. J Infect Dis 1988; 158 (3): 1046–1055.
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Bodey GP, Rinaldi MG. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis 1989; 8 (4): 323–330.
   PubMed Web of Science ®Google Scholar
• Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996; 9 (4): 499–511.
   PubMed Web of Science ®Google Scholar
• Hajjeh RA, Warnock DW. Counterpoint: invasive aspergillosis and the environment-rethinking our approach to prevention. Clin Infect Dis 2001; 33 (9): 1549–1552.
   PubMed Web of Science ®Google Scholar
• Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biolo-gy, and clinical aspects of Fusarium species. Clin Microbiol Rev 1994; 7 (4): 479–504.
   PubMed Web of Science ®Google Scholar
• Anaissie E, Kantarjian H, Ro J, et al. The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore) 1988; 67 (2): 77–83.
   PubMed Web of Science ®Google Scholar
• Ponton J, Ruchel R, Clemons KV, et al. Emerging pathogens. Med Mycol 2000; 38 Suppl 1: 225–236.
   PubMed Web of Science ®Google Scholar
• Etzel RA. Mycotoxins. JAMA 2002; 287 (4): 425-427.
   Google Scholar
• Conkova E, Laciakova A, Kovac G, Seidel H. Fusarial toxins and their role in animal diseases. Vet J 2003; 165 (3): 214–220.
   PubMed Web of Science ®Google Scholar
• Pitt JI. Toxigenic fungi: which are important? Med Mycol. 2000; 38 Suppl 1: 17–22.
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003; 98 (2): 315–319.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Hanna H, Hachem R, et al. Risk fac-tors of poor outcome of fusariosis in an tertiary care cancer center. Leukemia and Lymphoma, In press.
   Google Scholar
• Cohen MS, Isturiz RE, Malech HL, et al. Fungal infec-tion in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med 1981; 71 (1): 59–66.
   Google Scholar
• Torres HA, Bodey GP, Rolston KVI, Kantarjian HM, Raad II, Kontoyiannis DP. Infections in patients with aplastic anemia: experience at a tertiary care cancer center. Cancer 2003; in press.
   Google Scholar
• Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997; 10 (1): 86–124.
   PubMed Web of Science ®Google Scholar
• Sampathkumar P, Paya CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis. 2001; 32 (8): 1237–1240.
   PubMed Web of Science ®Google Scholar
• Cocuroccia B, Gaido J, Gubinelli E, Annessi G, Girolomoni G. Localized cutaneous hyalohyphomycosis caused by a fusarium species infection in a renal transplant patient. J Clin Microbiol 2003; 41 (2): 905–907.
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implica-tions for diagnosis and management. Clin Infect Dis 2002; 35 (8): 909–920.
   PubMed Web of Science ®Google Scholar
• Musa M O, Al Eisa A, Halim M, et al. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. Br J Haematol 2000; 108 (3): 544–548.
   PubMed Web of Science ®Google Scholar
• Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect. 2001; 7 Suppl 2: 8–24.
   PubMed Web of Science ®Google Scholar
• Raad I, Hachem R. Treatment of central venous catheter-related fungemia due to Fusarium oxysporum. Clin Infect Dis 1995; 20 (3): 709–711.
   PubMed Web of Science ®Google Scholar
• Donowitz GR, Maki DG, Crnich CJ, Pappas PG, Rolston KV. Infections in the neutropenic patient-new views of an old problem. Hematology (Am Soc Hematol Educ Program) 2001: 113–139.
   PubMedGoogle Scholar
• Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: a 10-year study. Clin Infect Dis 2000; 31 (1): 188–189.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Arcese W, Micozzi A, Martino P, Bianco P, Morace G. Onychomycosis as a possible origin of dissemi-nated Fusarium solani infection in a patient with severe aplastic anemia. Clin Infect Dis 1992; 14 (5): 1167.
   PubMed Web of Science ®Google Scholar
• Minor RL Jr, Pfaller MA, Gingrich RD, Burns U. Disseminated Fusarium infections in patients following bone marrow transplantation. Bone Marrow Transplant 1989; 4 (6): 653–658.
   PubMed Web of Science ®Google Scholar
• El-Ani AS. Disseminated infection caused by Fusarium solani in a patient with aplastic anemia. NY State J Med 1990; 90 (12): 609–610.
   PubMedGoogle Scholar
• Mohammedi I, Gachot B, Grossin M, Marche C, Wolff M, Vachon F. Overwhelming myocarditis due to Fusarium oxysporum following bone marrow transplantation. Scand J Infect Dis 1995; 27 (6): 643–644.
   PubMedGoogle Scholar
• Cho CT, Vats TS, Lowman JT, Brandsberg JW, Tosh FE. Fusarium solani infection during treatment for acute leukemia. J Pediatr 1973; 83 (6): 1028–1031.
   PubMed Web of Science ®Google Scholar
• Freidank H. Hyalohyphomycoses due to Fusarium spp.-two case reports and review of the literature. Mycoses 1995; 38 (1-2): 69-74.
   Google Scholar
• Fang CT, Chang SC, Tang IL, et al. Fusarium solani fungemia in a bone marrow transplant recipient. J Formos Med Assoc. 1997; 96 (2): 129–133.
   PubMed Web of Science ®Google Scholar
• Segal BH, Walsh TJ, Liu JM, Wilson JD, Kwon-Chung KJ. Invasive infection with Fusarium chlamydosporum in a patient with aplastic anemia. J Clin Microbiol 1998; 36 (6): 1772–1776.
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Estey E, Rex JH, et al. Intravenous itra-conazole for prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. 2001, Abstract J-831.
   Google Scholar
• Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis 1996; 22 Suppl 2: S112–118.
   PubMed Web of Science ®Google Scholar
• Warnock DW. Fungal infections in neutropenia: current problems and chemotherapeutic control. J Antimicrob Chemother 1998; 41 Suppl D: 95-105.
   Google Scholar
• Khoury H, Ball NJ. Disseminated fusariosis in a patient with acute leukaemia. Br J Haematol 2003; 120 (1): 1.
   PubMed Web of Science ®Google Scholar
• Consigny S, Dhedin N, Datry A, Choquet S, Leblond V, Chosidow O. Successful voriconazole treatment of dissemi-nated Fusarium infection in an immunocompromised patient. Clin Infect Dis 2003; 37 (2): 311–313.
   PubMed Web of Science ®Google Scholar
• Jakle C, Leek JC, Olson DA, Robbins DL. Septic arthritis due to Fusarium solani. J Rheumatol 1983; 10 (1): 151–153.
   PubMed Web of Science ®Google Scholar
• Young JB, Ahmed-Jushuf IH, Brownjohn AM, Parsons FM, Foulkes SJ, Evans EC. Opportunistic peritonitis in contin-uous ambulatory peritoneal dialysis. Clin Nephrol 1984; 22 (5): 268–269.
   PubMed Web of Science ®Google Scholar
• Nuovo MA, Simmonds JE, Chacho MS, McKitrick JC. Fusarium solani osteomyelitis with probable nosocomial spread. Am J Clin Pathol 1988; 90 (6): 738–741.
   PubMed Web of Science ®Google Scholar
• Agamanolis DP, Kalwinsky DK, Krill CE Jr, Dasu S, Halasa B, Galloway PG. Fusarium meningoencephalitis in a child with acute leukemia. Neuropediatrics 1991; 22 (2): 110–112.
   PubMed Web of Science ®Google Scholar
• Girardi M, Glusac EJ, Imaeda S. Subcutaneous Fusarium foot abscess in a renal transplant patient. Cutis 1999; 63 (5): 267–270.
   PubMed Web of Science ®Google Scholar
• Rolston KV. The spectrum of pulmonary infections in cancer patients. Curr Opin Oncol 2001; 13 (4): 218–223.
   PubMed Web of Science ®Google Scholar
• Kovacicova G, Spanik S, Kunova A, et al. Prospective study of fungaemia in a single cancer institution over a 10-year period: aetiology, risk factors, consumption of antifungals and outcome in 140 patients. Scand J Infect Dis 2001; 33 (5): 367–374.
   PubMedGoogle Scholar
• Hayden RT, Isotalo PA, Parrett T, et al. In situ hybridization for the differentiation of Aspergillus, fusarium, and pseudallescheria species in tissue section. Diagn Mol Pathol 2003; 12 (1): 21–26.
   PubMedGoogle Scholar
• Hennequin C, Abachin E, Symoens F, et al. Identification of Fusarium species involved in human infec-tions by 28S rRNA gene sequencing. J Clin Microbiol 1999; 37 (11): 3586–3589.
   PubMed Web of Science ®Google Scholar
• Bowman JC, Anderson JW, Liberator PA, Douglas CM. Quantitation of mycelial fungal pathogens by PCR. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego. 2002, Abstract M-910.
   Google Scholar
• Van Bunk JA, Myerson D, Schreckhise RW, Bowden RA. Panfungal PCR assay for detection of fungal infection in human blood specimens. J Clin Microbiol 1998; 36 (5): 1169–1175.
   PubMed Web of Science ®Google Scholar
• Capilla J, Ortoneda M, Pastor F J, Guarro J. In vitro antifungal activities of the new triazole UR-9825 against clini-cally important filamentous fungi. Antimicrob Agents Chemother 2001; 45 (9): 2635–2637.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002; 359 (9312): 1135–1144.
   PubMed Web of Science ®Google Scholar
• Speeleveld E, Gordts B, Van Landuyt HW, De Vroey C, Raes-Wuytack C. Susceptibility of clinical isolates of Fusarium to antifungal drugs. Mycoses 1996; 39 (1-2): 37–40.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Bartlett M, Bowden R, et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol 1997; 35 (1): 139–143.
   PubMed Web of Science ®Google Scholar
• Marco F, Pfaller MA, Messer SA, Jones RN. In vitro activity of a new triazole antifungal agent, SCH 56592, against clinical isolates of filamentous fungi. Mycopathologia 1998; 141 (2): 73–77.
   PubMed Web of Science ®Google Scholar
• Johnson EM, Szekely A, Warnock DW. In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens. Antimicrob Agents Chemother 1999; 43 (5): 1260–1263.
   PubMed Web of Science ®Google Scholar
• Li RK, Rinaldi MG. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother 1999; 43 (6): 1401–1405.
   PubMed Web of Science ®Google Scholar
• Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001; 45 (1): 327–330.
   PubMed Web of Science ®Google Scholar
• Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against fila-mentous fungi. J Antimicrob Chemother 1998; 42 (6): 741–745.
   PubMed Web of Science ®Google Scholar
• Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itra-conazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999; 37 (12): 3946–3951.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, Jones RN, and the SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B tested against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from the SENTRY antimicrobial surveillance pro-gram, 2000. Antimicrob Agents Chemother 2002; 46 (4): 1032-1037.
   Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new tria-zole antifungal agent. Clin Infect Dis 2003; 36 (5): 630–637.
   PubMed Web of Science ®Google Scholar
• Huczko E, Minassian B, Washo T, Bonner D, Fung-Tomc J. In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. 2001, Abstract J-810.
   Google Scholar
• Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro anti-fungal activities of voriconazole and reference agents as deter-mined by NCCLS methods: review of the literature. Mycopathologia 2001; 150 (3): 101–115.
   PubMed Web of Science ®Google Scholar
• Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro activities of investiga-tional triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother 2002; 46 (10): 3298–3300.
   PubMed Web of Science ®Google Scholar
• Reyes GH, Long L, Hossain M, Ghannoum MA. Evaluation of voriconazole efficacy in the treatment of murine fusariosis. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. 2001, Abstract J-1604.
   Google Scholar
• Fothergill AW, Rinaldi MG, Schwocho LR, Ohya S. Comparison of the investigational azole CS-758 (R-120758) to amphotericin B, fluconazole, and itraconazole against 250 mould fungi. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. 2002, Abstract J-822.
   Google Scholar
• Ortoneda M, Capilla J, Pastor FJ, Pujol I, Guarro J. Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis. Antimicrob Agents Chemother 2002; 46 (7): 2273–2275.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Comparison of in vitro activities of the new triazole 5CH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36 (10): 2950–2956.
   PubMed Web of Science ®Google Scholar
• Pfaller M A, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30 (4): 251–255.
   PubMed Web of Science ®Google Scholar
• Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44 (1): 57–62.
   PubMed Web of Science ®Google Scholar
• Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46 (1): 245–247.
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Matar MJ, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro synergy testing of anidulafungin and micafungin in combination with ampho-tericin B against Aspergillus spp and Fusarium spp. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego. 2002, Abstract M-1816.
   Google Scholar
• Stern GA. In vitro antibiotic synergism against ocular fungal isolates. Am J Ophthalmol 1978; 86 (3): 359–367.
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Nguyen MH. The combination of ampho-tericin B and azithromycin as a potential new therapeutic approach to fusariosis. J Antimicrob Chemother 1998; 41 (1): 127–130.
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Hachem R, Legrand C, Legenne P, Nelson P, Bodey GP. Lack of activity of amphotericin B in systemic murine fusarial infection. J Infect Dis 1992; 165 (6): 1155–1157.
   PubMed Web of Science ®Google Scholar
• Costa AR, Valente NY, Criado PR, Pires MC, Vasconcellos C. Invasive hyalohyphomycosis due to Fusarium solani in a patient with acute lymphocytic leukemia. Int J Dermatol 2000; 39 (9): 717–718.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26 (6): 1383–1396.
   PubMed Web of Science ®Google Scholar
• Comely OA, Rothe A, Hoppe T, et al. Terbinafine in combination with liposomal amphotericin B for successful treatment of Fusarium oxysporum fungemia despite long last-ing febrile neutropenia. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego. 2002, Abstract M-861.
   Google Scholar
• Lozano-Chiu M, Arikan S, Paetznick VL, Anaissie EJ, Loebenberg D, Rex JH. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother 1999; 43 (3): 589–591.
   PubMed Web of Science ®Google Scholar
• McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CR Jr, Rinaldi MG. In vitro activity of voriconazole against selected fungi. Med Mycol 1998; 36 (4): 239–242.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other inva-sive fungal infections in children. Pediatr Infect Dis J 2002; 21 (3): 240–248.
   PubMed Web of Science ®Google Scholar
• Rodriguez CA, Lujan-Zilbermann J, Woodard P, Andreansky M, Adderson EE. Successful treatment of dissemi-nated fusariosis. Bone Marrow Transplant 2003; 31 (5): 411–412.
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36 (9): 1122–1131.
   PubMed Web of Science ®Google Scholar
• Hachem R, Raad II, Afif C, et al. An open, non-com-parative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections refractory to or intolerant of standard therapy. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto. 2000, Abstract J-1109.
   Google Scholar
• Apostolidis J, Bouzani M, Platsouka E, et al. Resolution of fungemia due to fusarium species in a patient with acute leukemia treated with caspofungin. Clin Infect Dis 2003; 36 (10): 1349–1350.
   PubMed Web of Science ®Google Scholar
• Flynn JT, Meislich D, Kaiser BA, Polinsky MS, Baluarte HJ. Fusarium peritonitis in a child on peritoneal dialysis: case report and review of the literature. Pent Dial Int 1996; 16 (1): 52–57.
   PubMed Web of Science ®Google Scholar
• Farmaki E, Roilides E. Immunotherapy in patients with systemic mycoses: a promising adjunct. BioDrugs 2001; 15 (4): 207–214.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Adrian II, Grazziutti ML, Rex JH, Anaissie EJ. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis 1998; 26 (6): 1270-1278.
   Google Scholar
• Winn Rm, Maloukou A, Gil-Lamaignere C, Panteliadis C, Roilides E, The Eurofung Network. Interferon-gamma and granulocyte-macrophage colony stimulating factor enhance hyphal damage of Aspergillus and Fusarium spp by human neutrophils. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. 2001, Abstract J-134.
   Google Scholar
• Roilides E, Maloukou A, Gil-Lamaignere C, Winn RM, Panteliadis C, Walsh TJ. Differential effects of interleukin 15 on hyphal damage of filamentous fungi induced by human neutrophils. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. 2001, Abstract J-468.
   Google Scholar
• Anaissie EJ, Kuchar RT, Rex JH, et al. Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001; 33 (11): 1871–1878.
   PubMed Web of Science ®Google Scholar